MASI · NASDAQ
Price unavailable right now.
Average $180.29
The latest rating actions, newest first
| Firm | Date | Action | Rating |
|---|---|---|---|
| Raymond James | Mar 27, 2026 | Downgrade | Outperform → Market Perform |
| Wells Fargo | Feb 18, 2026 | Downgrade | Overweight → Equal-Weight |
| BTIG | Feb 18, 2026 | Downgrade | Buy → Neutral |
| BTIG | Dec 4, 2025 | Maintains | Buy |
| BTIG | Nov 24, 2025 | Maintains | Buy |
| B of A Securities | Nov 17, 2025 | Initiates | Neutral |
| Wells Fargo | Nov 5, 2025 | Maintains | Overweight |
| BTIG | Nov 5, 2025 | Maintains | Buy |
Updated May 26, 2026
Masimo is a solid company with a focused approach on healthcare technology, and their strategic priorities including focus, innovation, and execution will continue to drive growth and profitability. They are also heavily invested in research and development, with over 80 studies planned in the next three years, which will contribute to future revenue growth. The recent agreement with Danaher for a $9.9B cash acquisition shows the value and potential of Masimo's business.
Masimo is facing issues with predictable revenue due to fluctuations in installations and orders, as well as challenges with predicting quarterly revenue for their healthcare products. In comparison to other medical technology companies like Edwards Lifesciences Corporation and Intuitive Surgical, Inc., their financials and key metrics are relatively weaker, with slower integration of mergers and acquisitions, pricing pressure, and slower demand for capital equipment, making us have a negative outlook on the stock. However, risks to our rating and price target include unexpected positive announcements, potential improvements in competitive dynamics within the spine market, and better expense management, which could potentially increase the likelihood of achieving our $200 price target.
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.
